english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

FEATURED REVIEW Erenumab (Aimovig°) is a monoclonal antibody that has been authorised in the European Union for the prevention of migraine attacks in patients who experience attacks on more than 4 days a month. Prescrire's editorial staff have weighed the available evidence to bring you an unbiased assessment of the drug's harm-benefit balance.
Full review (5 pages) available for download by subscribers.
1 September 2019

In the September edition of Prescrire International: sartan medicines contaminated by impurities which are probable carcinogens

FREE DOWNLOAD The exposure of patients all around the world and over a period of several years to impurities which are known to be carcinogenic, and which were present in commonly used medicines, shows that the systems intended to guarantee pharmaceutical quality need to be improved.
Full text available for free download.
1 September 2019

Carpal tunnel syndrome: sometimes drug-related

Carpal tunnel syndrome is sometimes caused by certain drugs, and disappears when the medication is stopped.
1 September 2019

New drugs: investing in more informative clinical trials

More informative clinical trials are more expensive, but that is the price of better care.
1 September 2019

Fluoroquinolones: use should be restricted due to severe adverse effects

Given the many and sometimes severe adverse effects of fluoroquinolone antibiotics, they should only be used for limited purposes.
1 September 2019

"Top Texts of 2019", new from the editors of Prescrire International

 NEW: FREE SPECIAL EDITION  Check out this brand new sampling of texts selected by our editors to introduce you to Prescrire International, a wholly independent monthly journal, written by and for healthcare professionals
28 August 2019

Psychotic episode: which oral neuroleptic to choose? A choice tailored to each patient, based on the adverse effect profiles of the options

FEATURED REVIEW Neuroleptic drugs have been widely used since the 1950s to treat psychotic episodes. When an oral neuroleptic appears justified for treating a psychotic episode in an adult, which drug should be chosen?
Full review (7 pages) available for download by subscribers.
1 July 2019

In the July-August issue of Prescrire International: emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents

FREE DOWNLOAD Based on extrapolation of the data obtained in adults, the emtricitabine + tenofovir disoproxil combination (Truvada° or other brands) appears worth offering to adolescents whose sex practices place them at particularly high risk of contracting HIV infection.
Full text available for free download.
1 July 2019

Fentanyl (Actiq° and other brands) and other opioids: risk of increased pain

Paradoxically, fentanyl, like other opioids, can exacerbate the pain it is intended to relieve.
1 July 2019

Prescrire's packaging review for 2018: ways to reduce dangers

A drug's packaging (box, bottle, delivery device, leaflet, etc.) is especially important in preventing patient errors in taking the drug. Hence the usefulness of Prescrire's methodical analysis.
1 July 2019

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90